All Chapters of WIFE KICKED MILLIONAIRE MEDICAL GOD HUSBAND: Chapter 571
- Chapter 580
632 chapters
Chapter Five Hundred and Seventy One
Lukas read the pharmaceutical company's communication three times before he forwarded it to the council.He attached a single line of context: This is the decision they have forced us to make. I am not going to tell you what the right answer is. The communities involved should tell us.The council's response to the communication arrived over forty-eight hours, and Lukas read each message with the attention he brought to things that he could not make easier and that needed to be received completely.Dr. Okonkwo wrote: "The maternal health program in my region receives thirty percent of its funding from this company. Thirty percent is not survivable to lose in the short term. The program serves four thousand women annually. I need to be honest about that number when we discuss this."Dr. Kamau wrote: "In my region, the company funds the only reliable cold chain for vaccine distribution in three districts. If that funding is withdrawn, the disruption to immunization coverage will produce
Chapter Five Hundred and Seventy Two
Renske investigated the Swiss holding company and reported back in four days."The entity is a legitimate Swiss registered structure used for collective philanthropy," she told Lukas. "Three beneficial owners. One is identified in the registry as Abdullah Al-Mansour, Dutch resident, listed occupation as private investor."Lukas sat with this for a moment."Abdullah," he said."You know him," Renske said."Yes," he said. "He was a patient. Years ago, during a period when I had very few patients. He has referred people to me since and he has been consistently supportive." He paused. "He is also someone who has resources and who believes in what he thinks I represent, which is a dynamic I have navigated before with people whose support came with implications.""The other two beneficial owners," Renske said. "I am still working on identifying them through public records. The structure is designed for privacy but not for obscuring in ways that suggest anything problematic."Lukas called Ab
Chapter Five Hundred and Seventy Three
Renske's response to the standing motion took three weeks to prepare.The response was built around a straightforward argument: the communities whose knowledge was at issue had formally authorized the lawsuit through documented community council processes, the authorizations were attached as exhibits, and Lukas's role as named plaintiff was one component of a multi-party action in which the primary plaintiffs were the communities themselves, represented through their own governance structures.The response also addressed the pharmaceutical company's framing directly."The motion characterizes the plaintiff as a European practitioner speaking on behalf of non-European communities," Renske wrote. "This characterization misrepresents the structure of the case. The appropriate question is not whether Dr. Bauer has standing to represent communities he is not from, but whether those communities have standing to bring these claims and whether they have authorized these proceedings. The answe
Chapter Five Hundred and Seventy Four
Lukas began declining invitations in April.Not all of them and not without explanation. He replied to each declined invitation with a specific recommendation — a name, a brief description of the person's work and why they were better suited to this particular audience than he was, and an offer to facilitate the introduction.The first recommendation he made was Dr. Okonkwo for a keynote at a European public health conference that had invited him to speak about traditional knowledge protection. He contacted the conference organizers, explained his thinking, and proposed Dr. Okonkwo in his place.The conference organizers pushed back.They had built their communications around his name, they said. The audience was expecting the physician who had been involved in the pharmaceutical network investigation. Dr. Okonkwo was impressive but less known.Lukas replied that being less known was precisely part of the problem he was trying to address and that if the conference's interest was in tr
Chapter Five Hundred and Seventy Five
The council debated the trade association's request for three weeks before agreeing to respond.The debate was substantive in the way that the council's debates had become substantive since the restructuring, the full range of positions represented rather than converging quickly around what seemed most reasonable.Dr. Celestino Machava's position was the most skeptical."The legal case is proceeding," Dr. Celestino wrote. "The discovery evidence has damaged them publicly and legally. They are requesting dialogue now because dialogue is cheaper than the verdict that is coming. If we sit at their table before the verdict, we signal that the verdict is negotiable."Dr. Kamau's position was the opposite."The verdict is one outcome," Dr. Kamau wrote. "A court ruling that establishes legal precedent for one jurisdiction in one case. Industry-wide standards, if we can negotiate them, affect every pharmaceutical company in every jurisdiction for years. The potential scope of the negotiated o
Chapter Five Hundred and Seventy Six
Lukas shared the preprint with Renske before he shared it with the council.He wanted the legal analysis before the council discussion, because the discussion would need to happen with clarity about what the synthetic compound strategy meant legally rather than just ethically.Renske read the paper overnight and called him in the morning."The argument they are positioning for is conceptually clean," she said. "A synthesized compound, created through laboratory processes without extracting material from traditional sources, is a novel chemical entity under patent law. The novelty is established by the synthesis route, not by the compound's effects. If they can demonstrate that their synthesis was independently derived — even if the research program was guided by knowledge of traditional medicine effects — the patent claims are defensible under current frameworks.""Even if the research was guided by covertly documented traditional knowledge," Lukas said."That is where it becomes comp
Chapter Five Hundred and Seventy Seven
Lukas responded to Dr. Martinez's message with a single question: what protection do you need, and what protection do you think is actually available?He asked both questions because the gap between the two was where people making decisions like hers got hurt.Her response came two days later, longer and more detailed than the first message.Dr. Jennifer Martinez had been a research scientist for eleven years. Biochemistry background, specializing in pharmacognosy, the systematic study of medicines derived from natural sources. She had joined her current employer drawn by the research scope and the resources, and she had spent three years before the uncomfortable awareness had accumulated to the point where sitting with it quietly was no longer available.What she described as that awareness was consistent with what the discovery materials from the lawsuit had revealed, but more specific, more internal, carrying the granular texture of someone who had been inside the decision-making c
Chapter Five Hundred and Seventy Eight
Lukas spent two days verifying before he did anything else.He cross-referenced the project codes in Dr. Martinez's documents against the university's published research disclosures, the annual reports that listed industry partnerships and funding sources. The natural products chemistry group's pharmaceutical partnerships were disclosed, because the disclosure was required, though the specific project scope was described in terms that did not communicate what the cross-reference revealed.He read the published research outputs from the collaboration. The papers listed pharmaceutical company funding in the acknowledgments, as required. The research described was characterised as pharmacological investigation of compound mechanisms, language that was accurate about the methodology and that said nothing about where the compound candidates had originated.He identified three specific projects.One had produced a synthesis route for a compound whose traditional medicine analogue appeared i
Chapter Five Hundred and Seventy Nine
The meeting with Professor Andersen ended without resolution, which was the only honest ending available to it.Lukas returned to his office and sat for a while with what he had been told and what he had said and what was now in motion.He had not decided what to do before the meeting. He had decided only to present the findings and to hear the administration's response, because the response was information that he needed before any decision about what to do next was well-founded.The response had been the information.An institution that responds to the identification of potentially unethical research practices with a statement about the institutional costs of public criticism is an institution that has decided what it values and in what order.He wrote the account of the meeting in the document his lawyer was maintaining and sent it to her. Then he wrote a briefer version for the council.Dr. Asante's response: "The university's response is not surprising. It is the standard respons
Chapter Five Hundred and Eighty
Lukas drafted his conditions for accepting the committee chair in consultation with Sofie Dahl, Dr. Okonkwo, and his lawyer, the three people whose combined expertise covered institutional politics, community accountability, and legal enforceability.The conditions took two weeks to develop and were specific in ways designed to make the difference between genuine authority and performative authority visible.The committee must have the authority to issue a halt to any research program under review, effective immediately upon vote, pending full ethical assessment. Not the authority to recommend a halt to administrators who could override the recommendation. The authority to halt.The committee must include a minimum of three community representatives in contexts where the research involved traditional or indigenous knowledge, with full voting rights equal to academic members. Not advisory participation. Voting authority.The committee must publish all deliberations and decisions within